BIOLINERX LTD/S (NASDAQ:BLRX) Stock Crosses Above 200-Day Moving Average of $1.33

Share on StockTwits

BIOLINERX LTD/S (NASDAQ:BLRX)’s stock price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.33 and traded as high as $2.90. BIOLINERX LTD/S shares last traded at $2.85, with a volume of 9,630 shares trading hands.

BLRX has been the subject of several analyst reports. Maxim Group reiterated a “buy” rating and issued a $10.00 price objective on shares of BIOLINERX LTD/S in a research note on Monday, July 22nd. HC Wainwright reiterated a “neutral” rating on shares of BIOLINERX LTD/S in a research note on Wednesday, August 7th. Zacks Investment Research lowered shares of BIOLINERX LTD/S from a “buy” rating to a “hold” rating in a research note on Tuesday, July 16th. Finally, ValuEngine lowered shares of BIOLINERX LTD/S from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $4.13.

The company’s 50 day moving average price is $3.10 and its 200-day moving average price is $1.33. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.23 and a current ratio of 4.23. The company has a market cap of $21.69 million, a PE ratio of -0.89 and a beta of 1.60.

BIOLINERX LTD/S (NASDAQ:BLRX) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.65) by $0.61. Equities research analysts expect that BIOLINERX LTD/S will post -2.69 EPS for the current year.

Several hedge funds have recently modified their holdings of BLRX. Morgan Stanley increased its stake in shares of BIOLINERX LTD/S by 50.6% during the 2nd quarter. Morgan Stanley now owns 1,421,862 shares of the biotechnology company’s stock worth $519,000 after purchasing an additional 477,798 shares during the last quarter. Delek Group Ltd. purchased a new stake in shares of BIOLINERX LTD/S during the 1st quarter worth approximately $92,000. Deutsche Bank AG purchased a new stake in shares of BIOLINERX LTD/S during the 4th quarter worth approximately $26,000. Finally, NEXT Financial Group Inc increased its stake in shares of BIOLINERX LTD/S by 82.5% during the 2nd quarter. NEXT Financial Group Inc now owns 73,000 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 33,000 shares during the last quarter.

BIOLINERX LTD/S Company Profile (NASDAQ:BLRX)

BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.

Further Reading: What is Cost of Debt?

Receive News & Ratings for BIOLINERX LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.